Abruzzo L.V., Jaffe E.S., Cotelingam J.D., Whang-Peng J., Del Luca V., Medeiros L.J. 1992. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am. J. Surg. Pathol. 16: 236-245.

Adams J.M., Cory S. 2001. Life-or-death decisions by the Bcl-2 protein family. Trends. Biochem. Sci. 26: 61-66.

Adnane J., Gaudray P., Dionne C.A., Crumley G., Jaye M., Schlessinger J., Jeanteur P., Birnbaum D., Theillet C. 1991. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 6: 659-663.

Afar D.E.H., Han L., McLaughlin J., Wong S., Dhaka A., Parmar K., Rosenberg N., Witte O.N., Colicelli J. 1997. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity. 6: 773-782.

Aguiar R.C.T., Chase A., Coulthard S., MacDonald D.H.C., Carapeti M., Reiter A., Sohal J., Lennard A., Goldman J.M., Cross N.C.P. 1997. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood. 90: 3130-3135.

Akagi T., Shishido T., Murata K., Hanafusa H. 2000. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc. Natl. Acad. Sci. 97: 7290-7295.

Albitar M., Freireich E.J. 2000. Molecular defects in chronic myeloproliferative disorders. Mol. Med. 6: 555-567.

Alexander W.S., Nicola N.A. 1998. Hemopoietic growth factor receptor abnormalities in leukemia. Leukemia Res. 22: 1097-1111.

Allouche M. 1995. Basic fibroblast growth factor and hematopoiesis. Leukemia. 9: 937-942.

Anderson J., Burns HD., Enriquez-Harris P., Wilkie AO., Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum. Mol. genet. 7: 1475-1483.

Aoki M., Blazek E., Vogt P.K. 2001. A role of the kinase mTOR in cellular transformation induced by the oncoprotein P3k and Akt. Proc. Natl. Acad. Sci. 98: 136-141.

Arese M., Chen Y., Florkiewicz R.Z., Gualandris A., Shen B., Rifkin D.B. 1999. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol. Cell. Biol. 10: 1429-1444.

Arnould C., Philippe C., Bourdon V., Gregoire M.J., Berger R., Jonveaux P. 1999. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum. Mol. Genet. 8: 1741-1749.

Bai R-Y., Ouyang T., Miething C., Morris S.W., Peschel C., Duyster J. 2000. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 96: 4319-4327.

Balmain A. 2001. Cancer genetics: from Boveri and Mendel to microarrays. Nature reviews. 1: 77-82.

Barker S.A., Lujan D., Wilson B.S. 1999. Multiple roles for PI 3-kinase in the regulation of PLCg activity and Ca²⁺ mobilization in antigen-stimulated mast cells. J. Leuk. Biol. 65: 321-329.

Barlund M., Monni O., Kononen J., Cornelison R., Torhorst J., Sauter G., Kallioniemi O.P., Kallioniemi A. 2000. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 60: 5340-5344.

Barr FG. 1998. Translocations, cancer and the puzzle of specificity. Nature Genet. 19: 121-124.

Behringer D., Schaefer H.E., Kunzmann R., Mertelsmann R., Dölken G. 1995. Translocation t(8;13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome. Leukemia. 9: 988-992.

Beiman M., Shilo B-Z., Volk T. 1996. Heartless, a drosophila FGF receptor homolog, is essential for cell migration and establishment of several mesodermal lineages. Genes Dev. 10: 2993-3002.

Bellot F., Crumley G., Kaplow J.M., Schlessinger J., Jaye M., and Dionne C.A. 1991. Ligand-induced transphosphorylation between different FGF receptors. EMBO J. 10: 2849-2854.

Bellus GA., McIntosh I., Smith EA., Aylsworth AS., Kaitila I., Horton WA., Greenhaw GA., Hecht JT., Francomano CA. 1995. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nature Genet. 10: 357-359.

Bellus G.A., Gaudenz K., Zackai E.H., Clarke L.A., Szabo J., Francomano C.A., Muenke M. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. 1996. Nature Genet. 14: 174-176.

Bellus G.A., Bamshad M.J., Przylepa K.A., Dorst J., Lee R.R., Hurko O., Jabs E.W., Curry C.J., Wilcox W.R., Lachman R.S., Rimoin D.L., Francomano C.A. 1999. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am. J. Med. Genet. 85: 53-65.

Bennet J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D., Gralnick H.R., and Sultan C. 1985. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Of Int. Med. 103: 626-629.

Berardi A.C., Wang A., Abraham J., Scaden D.T. 1995. Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells. Blood. 86: 2123-2129.

Beviglia L., Matsumoto K., Lin C.S., Ziober B.L., Kramer R.H. 1997. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int. J. Cancer. 74: 301-309.

Biernaux C., Loos M., Sels A., Huez G., Stryckmans P. 1995. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 86: 3118-3122.

Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., Bralet M.P., Lefrere-Belda M.A., Lahaye J.B., Abbou C.C., Bonaventure J., Zafrani E.S., van der Kwast T., Thiery J.P., Radvanyi F. 2001. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158: 1955-1959.

Blume-Jensen P., Hunter T. 2001. Oncogenic kinase signalling. Nature. 411: 355-365.

Bodine D.M., Karlsson S., Nienhuis A.W. 1989. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc. Natl. Acad. Sci. 86: 8897-8901.

Boget S., Cereser C., Parvaz P., Leriche A., Revol A. 2001. Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not. Eur. J. Endocrinol. 145: 303-310.

Bonfini L., Migliaccio E., Pelicci G., Lanfrancone L., Pelicci P. 1996. Not all shc’s roads lead to ras. Trends Biochem. Sci. 21: 257-261.

Borg JP., Ooi J., Levy E., Margolis B. 1996. The PI domain of X11 and FE65 bind to distinct site on the YENPTY motif of amyloid precursor protein. Mol. Cell. Biol. 16: 6229-6241.

Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S.K., Civin C.I., Disteche C., Dubé I., Frischauf A.M., Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E. 1996a. The translocation t(8;16)(p11;p13) of acute myeloid leukemia fuses a putative acetyl transferase to the CREB-binding protein. Nat. Genet. 14: 33-41.

Borrow J., Shearman AM., Stanton V.P., Becher R., Collins T., Williams AJ., Dubé I., Katz F., Kwong YL., Morris C., Ohyashiki K., Toyama K., Rowley J., Housman D.E. 1996b. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat. Genet. 12: 159-167.

Bose S., Deininger M., Gora-Tybor J., Goldman JM., Melo J.V.1998. The presence of typical and atypical BCR-ABL fusion genes in leucocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood. 92: 3362-3367.

Bottaro D.P., Rubin J.S., Ron D., Finch P.W., Florio C., Aaronson S.A. 1990. Characterization of the receptor for keratinocyte growth factor. J. Biol. Chem. 265: 12767-12770.

Bowman T., Garcia R., Turkson J., Jove R. 2000. STATs in oncogenesis. Oncogene. 19: 2474-2488.

Brazil D.P., Hemmings B.A. 2001. Ten years of protein kinase B signalling: a hard Akt to follow. Trends in Biochem. Sci. 26: 657-664.

Bromberg J.F. 2001. Activation of STAT proteins and growth control. BioEssays. 23: 161-169.

Broutin I., Ducruix A. 2000. Domaines structuraux et signalisation. Medecine/ Sciences. 16: 611-616.

Browaeys-Poly E., Cailliau K., Vilain J.P. 2000. Signal transduction pathways triggered by fibroblast growth factor receptor 1 expressed in Xenopus laevis oocytes after fibroblast growth factor 1 addition. Eur. J. Biochem. 267: 6256-6263.

Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. 1999. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 96: 857-868.

Brunn G.J., Hudson C.C., Sekulic A., Williams J.M., Hosoi H., Houghton P.J., Lawrence J.C., Abraham R.T. 1997. Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin. Science. 277: 99-101.

Burel SA., Harakawa N., Zhou L., Pabst T., Tenen DG., Zhang D. 2001. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol. Cell. Biol. 16: 5577-5590.

Burgar H.R., Burns H.D., Elsden J.L., Lalioti M.D., Heath J.K. 2001. Association of the signalling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain. J. Biol. Chem. in press.

Burgering B.M.Th. Coffer P.J. 1995. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 376: 599-602.

Burke D., Wilkes D., Blundell TL., Malcolm S. 1998. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem. Sci. 23: 59-62.

Butti M.G., Bongarzone I., Ferraresi G., Mondellini P., Borrello M.G., Pierotti M.A. 1995. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics. 28: 15-24.

Cantley L.C., Neel B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. 96: 4240-4245.

Cappellen D., De Oliveira C., Ricol D., de Medina S.G.D., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet. 23: 18-20.

Carapeti M., Aguiar R.C.T., Goldman J.M., Cross N.C.P. 1998. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 91: 3127-3133.

Carballada R., Yasuo H., Lemaire P. 2001. Phosphatidylinositol-3 kinase acts in parallel to the ERK MAP kinase in the FGF pathway during Xenopus mesoderm induction. Development. 128: 35-44.

Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282: 1318-1321.

Carlesso N., Frank D.A., Griffin J.D. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J.Exp. Med. 183: 811-820.

Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., Wells S.A., Goodfellow P.J., Donis-Keller H. 1994. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. 91: 1579-1583.

Carron C., Cormier F., Janin A., Lacronique V., Giovannini M., Daniel M.T., Bernard O., Ghysdael J. 2000. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 95: 3891-3899.

Casci T., Vinos J., Freeman M. 1999. Sprouty, an intracellular inhibitor of Ras signaling. Cell. 96: 655-665.

Castellanos A., Pintado B., Weruaga E., Arévalo R., Lopez A., Orfao A., Sanchez-Garcia I. 1997. A BCR-ABL ^p190 fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood. 90: 2168-2174.

Chaffanet M., Popovici C., Leroux D., Jacrot M., Adelaïde J., Dastugue N., Grégoire M-J., Lafage Pochitaloff M., Birnbaum D., and Pébusque M-J. 1998. t(6;8), t(8;9) and t(8;13) translocations associated with myeloproliferative disorders have close or identical breakpoints on chromosome 8p11-12. Oncogene. 16: 945-949.

Chaffanet M., Mozziconacci M.J., Fernandez F., Sainty D., Lafage-Potchitaloff M., Birnbaum D., Pébusque M.J. 1999. A case of inv(8)(p11q24) associated with acute myeloid leukemia involves the MOZ and CBP genes in a masked t(8;16). Genes Chrom. Cancer. 26: 161-165.

Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D., Pébusque M.J. 2000. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chrom. Cancer. 28: 138-144.

Champagne N., Pelletier N., Yang X-J. 2001. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. Oncogene. 20: 404-409.

Chang C.P., Jacobs Y., Nakamura T., Jenkins N.A., Copeland N.G., Cleary M.L. 1997. Meis proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins. Mol. Cell. Biol. 17: 5679-5687.

Chang L., Karin M. 2001. Mammalian MAP kinase signalling cascades. Nature. 410: 37-40.

Charbord P. 1998. Le micro-environnement médullaire chez l’homme normal et pathologique. Hématologie. 4: 29-40.

Chaudhuri MM., Moscatelli D., Basilico C. 1993. Involvement of the conserved acidic amino acid domain of FGF Receptor 1 in ligand-receptor interaction. J. Cell. Physiol. 157: 209-216.

Chen Z., Brand N., Chen A., Chen S.J., Tong J.H., Wang Z.Y., Waxman S., Zelent A. 1993. Fusion between a novel kruppel-like zinc finger gene and the retinoic acid receptor a locus due to a variant t(11;17) translocation in acute promyelocytic leukemia. EMBO J. 12: 1161-1167.

Chen Y., Li X., Eswarakumar V.P., Seger R., Lonai P. 2000. Fibroblast growth factor (FGF) signalling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation. Oncogene. 19: 3750-3756.

Cheng JQ., Ruggeri B., Klein WM., Sonoda G., Altomare DA., Watson DK., Testa JR. 1996. Amplification of AKT2 in human pancreatic-cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA. 93: 3636-3641.

Chernova O., Still I., Kalaycio M., Hoeltge G., Cowell J.K. 1998. Characterization of the breakpoints in a t(8;13)(p11;q12) translocation from a patient with myeloproliferative disease using fluorescence in situ hybridization. Genes Chrom. Cancer. 21: 160-165.

Chesi M., Nardini E., Brents LA., Schrock E., Ried T., Kuehl WM., and Bergsagel PL. 1997. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16: 260-264.

Chesi M., Brents LA., Ely SA., Bais C., Robbiani DF., Mesri EA., Kuehl WM., and Bergsagel PL. 2001. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 97(3): 729-736.

Chou M.M., Blenis J. 1995. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Cur. Op. Cell Biol. 7: 806-814.

Chung J., Grammer T.C., Lemon K.P., Kazlauskas A., Blenis J. 1994. PDGF- and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH-kinase. Nature. 370: 71-75.

Cirinnà M., Trotta R., Salomoni P., Kossev P., Wasik M., Perrotti D., Calabretta B. 2000. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood. 96: 3915-3921.

Cleary ML. 1991. Oncogenic conversion of transcription factors by chromosomal translocations. Cell. 66: 619-622.

Cobaleda C., Pérez-Losada J., Sanchez-Garcia I. 1998. Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms. BioEssays. 20: 922-930.

Coffer PJ., Jin J., Woodgett JR. 1998. Protein kinase B (c-AKT): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335: 1-13.

Cohen P., Frame S. 2001. The renaissance of GSK3. Nature Mol. Cell. Biol. 2: 769-776.

Constantino Rosa Santos S., Dumon S., Mayeux P., Gisselbrecht S., Gouilleux F. 2000. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene. 19: 1164-1172.

Constantino Rosa Santos S., Lacronique V., Bouchaert I., Monni R., Bernard O., Gisselbrecht S., Gouilleux F. 2001a. Constitutively active STAT5 variants induce growyh and survival of hematopoietic cells through a PI3-kinase/Akt dependant pathway. Oncogene. 20: 2080-2090.

Constantino Rosa Santos S., Monni R., Bouchaert I., Bernard O., Gisselbrecht S., Gouilleux F., Lacronique V. 2001b. Involvement of the NF-kB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Letters. 497: 148-152.

Cortez D., Kadlec L., Pendergast A.M. 1995. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15: 5531-5541.

Coulthard S., Chase A., Orchard K., Watmore A., Vora A., Goldman J.M., Swirsky D.M. 1998. Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant. Br. J. Haematol. 100: 561-563.

Coulier F., Pontarotti P., Roubin R., Hartung H., Goldfarb M., Birnbaum D. 1997. Of worms and men: an evoultionary perspective on the fibroblast growth factor (FGF) and FGF receptor familes. J. Mol. Evol. 44: 43-56.

Craddock B.L., Orchiston E.A., Hinton H.J., Welham M.J. 1999. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling. J. Biol. Chem. 274: 10633-10640.

Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378: 785-789.

Cross M.J., Hodgkin M.N., Roberts S., Landgren E., Wakelam M.J.O., Claesson-Welsh L. 2000. Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A2, phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J. Cell Sci. 113: 643-651.

Cryns V., Yuan J. 1998. Proteases to die for. Genes dev. 12: 1551-1570.

Daley G.Q., Van Etten R.A., Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the p210 ^bcr/abl gene of the philadelphia chromosome. Science. 247: 824-830.

Dash A., Gilliland D.G. 2001. Molecular genetics of acute myeloid leukaemia. Best Practice Res. Clin. Haematol. 14: 50-64.

Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91: 231-241.

Datta S.R., Brunet A., and Greenberg M.E. 1999. Cellular survival: a play in three Akts. Genes Dev. 13: 2905-2927.

Datta S.R., Katsov A., Hu L., Petros A., Fesik S.W., Yaffe M.B., Greenberg M.E. 2000. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell. 6: 41-51.

Deininger M.W.N., Goldman J.M., and Melo J.V. 2000. The molecular biology of chronic myeloid leukemia. Blood. 96: 3343-3356.

Dell’Era P., Mohammadi M., Presta M. 1999. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. Mol. Biol. Cell. 10: 23-33.

Del Peso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G. 1997. Interleukin-3 induced phosphorylation of BAD through the protein kinase Akt. Science. 278: 687-689.

Demiroglu A., Steer E.J., Heath C., Taylor K., Bentley M., Allen S.L., Koduru P., Brody J.P., Hawson G., Rodwell R., Doody M.L., Carnicero F., Reiter A., Goldman J.M., Melo J.V., Cross N.C.P. 2001. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 98: 3778-3783.

Deng C.X., Wynshaw-Boris A., Shen M.M., Daugherty C., Ornitz D.M., Leder P. 1994. Murine FGFR1 is required for early postimplantation growth and axial organization. Genes Dev. 8: 3045-3057.

Deng X., Ruvolo P., Carr B., May W.S. 2000. Survival function of ERK1/2 as IL-3-activated staurosporine-resistant Bcl2 kinases. Proc. Natl. Acad. Sci. 97: 1578-1583.

Desmaze C., Brizard F., Turc-Carel C., Melot T., Delattre O., Thomas G., Aurias A. 1997. Multiple chromosomal mechanisms generate an EWS/FLI1 or EWS/ERG fusion gene in Ewing tumors. Cancer Genet. Cytogenet. 97: 12-19.

Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. 1998. IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17: 2215-2223.

DeVita Jr. V.T., and Canellos G.P. 1999. The Lymphomas. Seminars in Hematol. 36 suppl.7: 84-94.

DeVore D.L., Horvitz H.R., Stern M.J. 1995. An FGF-receptor signaling pathway is required for the normal cell migrations of the sex myoblasts in C. elegans hermaphrodites. Cell. 83: 611-620.

Dickstein J.I., and Vardiman J.W. 1995. Hematopathologic Findings in the Myeloproliferative Disorders. Seminars in Oncol. 22: 355-373.

Dionne C.A., Crumley G., Bellot F., Kaplow J.M., Searfoss G., Ruta M., Burgess W.H., Jaye M., Schlessinger J. 1990. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J. 9: 2685-2692.

Dominguez I., Green J.B.A. 2001. Missing links in GSK3 regulation. Dev. Biol. 235: 303-313.

Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. 1993. Mutations in the RET proto-oncogene are associated with MEN 2A and FTMC. Hum. Mol. Genet. 2: 851-856.

Downward J. 1999. How BAD phosphorylation is good for survival. Nat. Cell Biol. E33-E35.

Drexler H.G., MacLeod RAF., Borkhardt A., and Janssen JWG. 1995. Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines. Leukemia. 9: 480-500.

Druker B. 2001. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin. Hematol. 38: 9-14.

Dunican D.J., Williams E.J., Howell F.V., Doherty P. 2001. Selective inhibition of fibroblast growth factor (FGF)-stimulated mitogenesis by a FGF receptor-1-derived phosphopeptide. Cell Growth Diff. 12: 255-264.

Elefanty A.G., Cory S. 1992. Hematologic disease induced in Balb/c mice by a bcr-abl retrovirus is influenced by the infection conditions. Mol. Cell. Biol. 12: 1755-1763.

Elsner S., Martin H., Rode C., Wassmann B., Ganser A., Hoelzer D. 1994. An uncommon translocation t(6;8) associated with atypical acute myeloid leukemia/myeloproliferative disease detected by fluorescence in situ hybridization. Br. J. Haematol. 87 (suppl. 1): 124.

Engels I.H., Stepczynska A., Stroh C., Lauber K., Berg C., Schwenzer R., Wajant H., Jänicke R.U., Porter A.G., Belka C., Gregor M., Schulze-Osthoff K., Wesselborg S. 2000. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene. 19: 4563-4573.

Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.M., Yang-Yen H.F., Karras J., Jove R., Loughran T.P. 2001. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Investig. 107: 351-362.

Erhardt P., Schremser E.J., Cooper G.M. 1999. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 19: 5308-5315.

Evan G.I., Vousden K.H. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature. 411: 342-348.

Ezoe K., Holmes SA., Ho L., Bennett CP., Bolognia JL., Brueton L., Burn J., Falabella R., Gatto EM., Ishii N., Moss C., Pittelkow M.R., Thompson E., Ward A., Spritz R.A. 1995. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am. J. Hum. Genet. 56: 58-66.

Fagan K., Hyde S., Harrison P. 1993. Translocation (8;13) and T-cell lymphoma. A case report. Cancer Genet. Cytogenet. 65: 71-73.

Fan S., Ma Y.X., Gao M., Yuan R.Q., Meng Q., Goldberg I.D., Rosen E.M. 2001. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signalling for cell survival and DNA repair. Mol. Cell. Biol. 21: 4968-4984.

Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., Trzaskos J.M. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273: 18623-18632.

Feller S.M. 2001. Crk family adaptors-signalling complex formation and biological roles. Oncogene. 20: 6348-6371.

Fenrick R., Amann J.M., Lutterbach B., Wang L., Westendorf J.J., Downing J.R., Hiebert S.W. 1999. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol. Cell. Biol. 19: 6566-6574.

Ferracini R., Di Renzo M.F., Scotlandi K., Baldini N., Olivero M., Lollini P., Cremona O., Campanici M., Comoglio P.M. 1995. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 10: 739-749.

Fioretos T., Panagopoulos I., Lassen C., Swedin A., Billström R., Isaksson M., Strömbeck B., Olofsson T., Mitelman F., Johansson B. 2001. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chrom. Cancer. 32: 302-310.

Fischer S., Gisselbrecht S. 1998. Inhibition de l’apoptose: une des fonctions de la kinase Akt/PKB. Hématologie. 4: 102-106.

Flandrin G., 2001. La nouvelle classification OMS des hémopathies malignes. Hématologie. 7: 136-141.

Fleming T.P., Saxena A., Clark W.C., Robertson J.T., Oldfield E.H., Aaronson S.A., Ali I.U. 1992. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52: 4550-4553.

Foehr E.D., Raffioni S., Murray-Rust J., Bradshaw R.A. 2001. The role of tyrosine residues in fibroblast growth factor receptor 1 signaling in PC12 cells. J. Biol. Chem. 276: 37529-37536.

Forestell S.P., Dando J.S., Bohnlein E., Rigg R.J. 1996. Improved detection of replication-competent retrovirus. J. Virol. Methods. 60: 171-178.

Franke T.F., Kaplan D.R., Cantley L.C. 1997a. PI3K: downstream AKTion blocks apoptosis. Cell. 88: 435-437.

Franke T.F., Kaplan D.R., Cantley L.C., Toker A. 1997b. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 275: 665-668.

Friedhoff F., Rajendra B., Moody R., Alapatt T. 1983. Novel reciprocal translocation between chromosomes 8 and 9 found in a patient with myeloproliferative disorder. Cancer Genet. Cytogenet. 9: 391-394.

Galvin B.D., Hart K.C., Meyer A.N., Webster M.K., Donoghue D.J. 1996. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR) 2 and FGFR2/Neu chimeras. Proc. Natl. Acad. Sci. 93: 7894-7899.

Geoerger B., Kerr K., Tang C.B., Fung K.M., Powell B., Sutton L.N., Phillips P.C., Janss A.J. 2001. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Research. 61: 1527-1532.

Gesbert F., Griffin J.D. 2000. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 96: 2269-2276.

Gibbs J.B., Oliff A., Kohl N.E. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77: 175-178.

Gilliland D.G. 2001. Hematologic malignancies. Curr. Op. Hematol. 8: 189-191.

Goga A., McLaughlin J., Afar D.E.H., Saffran D.C., Witte O.N. 1995. Alternative signals to Ras for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82: 981-988.

Goldfarb M. 1990. The fibroblast factor family. Cell Growth Differ. 1: 439-445.

Golub T., Barker G.F., Bohlander S., Hiebert S.W., Ward D.C., Bray-Ward P., Morgan E., Raimondi S.C., Rowley J.D., and Gilliland D.G. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. 92: 4917-4921.

Golub T.R., Goga A., Barker G.F., Afar D.E., McLaughlin J., Bohlander S.K., Rowley J.D., Witte O.N., and Gilliland D.G. 1996. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol. 16: 4107-4116.

Golub T.R., Barker G.F., Stegmaier K., and Gilliland D.G. 1997. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Current Topics Microbiol. Immunol. 220: 67-79.

Gordon M.Y., Dazzi F., Marley S.B., Lewis J.L., Nguyen D., Grand F.H., Davidson R.J., and Goldman J.M. 1999. Cell biology of CML cells. Leukemia. 13, suppl. 1: S65-S71.

Gorman D.M., Cotter T.G. 2001. Molecular signals in anti-apoptotic survival pathways. Leukemia. 15: 21-34.

Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., Johnson D.E., Huang L., He Y., Kim J.D. 2000. Constitutive activation of STAT3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. 97: 4227-4232.

Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C., Della Porta G. 1992. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene. 7: 237-242.

Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M., Pierotti M.A. 1995. The DNA rearrangement that generates TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell. Biol. 15: 6118-6127.

Grigelioniene G., Hagenas L., Eklof O., Neumeyer L., Haereid P.E., Anvret M. 1998. A novel missense mutation Ile258Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Hum. Mutat. 11: 333.

Gross A., McDonnell JM., Korsmeyer S.J. 1999a. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899-1911.

Gross A.W., Zhang X., Ren R. 1999b. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol. Cell. Biol. 19: 6918-6928.

Gross I., Bassit B., Benezra M., Licht J.D. 2001. Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J. Biol. chem. 276: 46460-46468.

Gu H., Maeda H., Moon J.J., Lord J.D., Yoakim M., Nelson B.H., and Neel B.G. 2000. New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway. Mol.Cell.Biol. 20: 7109-7120.

Guasch G., Mack G.J., Popovici C., Dastuge N., Birnbaum D., Rattner J.B., Pébusque M-J., 2000. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 95: 1788-1796.

Hadari YR., Kouhara H., Lax I., Schlessinger J. 1998. Binding of SHP2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol. Cell. Biol. 18: 3966-3973.

Haldar S., Jena N., Croce C.M. 1995. Inactivation of Bcl-2 by phosphorylation. Proc. Natl Acad. Sci. 92: 4507-4511.

Hall H., Williams E.J., Moore S.E., Walsh F.S., Prochiantz A., Doherty P. 1996. Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Current Biol. 6: 580-587.

Haluska FG., Tsujimoto Y., Croce CM. 1987. The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occured during immunoglobulin gene rearrangement and involved the heavy chain diversity region. Proc. Natl. Acad. Sci. USA. 84: 6835-6839.

Hamilton E., Miller K.M., Helm K.M., Langdon W.Y., Anderson S.M. 2001. Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl. J. Biol. Chem. 276: 9028-9037.

Hanahan D., Weinberg R.A. 2000. The hallmarks of cancer. Cell. 100: 57-70.

Hanenberg H., Xiao X.L., Dilloo D., Hashino K., Kato I., Williams D.A. 1996. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med. 2: 876-882.

Hanks S.K., and Hunter T. 1995. Protein kinases 6. The eukaryotic protein kinase superfamily : kinase (catalytic) domain structure and classification. FASEB J. 9: 576-596.

Hannemann J.R., McManus D.M., Kabarowski J.H.S., Wiedemann L.M. 1998. Haemopoietic transformation by the TEL/ABL oncogene. British. J. of Haematol. 102: 475-485.

Hara K., Yonezawa K., Sakaue H., Ando A., Kotani K., Kitamura T., Kitamura Y., Ueda H., Stephens L., Jackson T.R., Hawkins P.T., Dhand R., Clark A.E., Holman G.D., Waterfield M.D., Kasuga M. 1994 1-phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc. Natl. Acad. Sci. 91: 7415-7419.

Hara K., Yonezawa K., Sakaue H., Kotani K., Kojima A., Waterfield M.D., Kasuga M. 1995. Normal activation of P70 S6 kinase by insulin in cells overexpressing dominant negative 85kD subunit of phosphoinositide 3-kinase. Biochem. Biophys. Res. Commun. 208: 735-741.

Hara K., Yonezawa K., Kozlowski M.T., Sugimoto T., Andrabi K., Weng Q.P., Kasuga M., Nishimoto I., Avruch J. 1997. Regulation of elF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272: 26457-26463.

Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J. 2000. Transformation and STAT activation by derivatives of FGFR1, FGFR3 and FGFR4. Oncogene. 19: 3309-3320.

Hart K.C., Robertson S.C., Donoghue D.J. 2001. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol. Biol. Cell. 12: 931-942.

Hawley R.G., Lieu F.H.L., Fong A.Z.C., and Hawley T.S. 1994. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1: 136-138.

Hawley R.G., Fong A.Z.C., Ngan B.-Y., Hawley T.S. 1995. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene. 11: 1113-1123.

Hecht J.L., Aster J.C. 2000. Molecular biology of Burkitt’s lymphoma. J. Clin. Oncol. 18: 3707-3721.

Heldin C.H. 1996. Protein tyrosine kinase receptors. Cancer Surv. 27: 7-24.

Helou K., Wallenius V., Qiu Y., Öhman F., Stahl F., Klinga-Levan K., Kindblom L.G., Mandahl N., Jansson J.O., Levan G. 1999. Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas. Oncogene. 18: 3226-3234.

Hengartner M.O. 2000. The biochemistry of apoptosis. Nature. 407: 770-776.

Hernandez L., Pinyol M., Hernadez S., Bea S., Pulford K., Rosenwald A., Lamant L., Falini B., Ott G., Mason D.Y., Delsol G., and Campo E. 1999. TRK-Fused Gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood. 94: 3265-3268.

Hiebert S.W., Sun W., Davis N., Golub T., Shurtleff S., Buijs A., Downing JR., Grosveld G., Roussel M.F., Gilliland D.G., Lenny N., Meyers S. 1996. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol. 16: 1349-1355.

Hiebert S.W., Lutterbach B., Amann J. 2001. Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21) and inv(16) fusion proteins. Cur. Op. Hematol. 8: 197-200.

Hinton H.J., Welham M.J. 1999. Cytokine-induced protein kinase B activation and Bad phosphorylation do not correlate with cell survival of hematopoietic cells. J. Immunology. 162: 7002-7009.

Ho J.M.Y., Beattie B.K., Squire J.A., Frank D.A., Barber D.L. 1999. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 93: 4354-4364.

Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Höppener J.W.M., van Amstel H.K.P., Romeo G., Lips C.J.M., Buys C.H.C.M. 1994. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367: 375-376.

Holgado- Madruga M., Emlet D.R., Moscatello D.K., Godwin A.K., Wong A.J. 1996. Nature. 379: 560-564.

Holliday R. 1989. Chromosome error propagation and cancer. Trends Genet. 5: 42-45

Honda H., Oda H., Suzuki T., Takahashi T., Witte O.N., Ozawa K., Ishikawa T., Yazaki Y., Hirai H. 1998. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210^bcr/abl: a novel transgenic model for human Ph¹-positive leukemias. Blood. 91: 2067-2075.

Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A. 1999. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-dependent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59: 886-894.

Huang J., Mohammadi M., Rodrigues G.A., Schlessinger J. 1995. Reduced activation of RAF-1 and MAP Kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis. J. Biol. Chem. 270: 5065-5072.

Hubbard S.R., Mohammadi M., Schlessinger J. 1998. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273: 11987-11990.

Hubbard S.R., Till J.H. 2000. Protein tyrosine kinase stucture and function. Annu. Rev. Biochem. 69: 373-398.

Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet. 24: 57-60.

Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M.,Mohammadi M. 2001. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. . Proc. Natl. Acad. Sci. USA. 98: 7182-7187.

Ilaria R.L., Van Etten R.A. 1996. P210 and P190 ^BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271: 31704-31710.

Inhorn R.C., Aster J.C., Roach S.A., Slapak C.A., Soiffer R., Tantravahi R., Stone R.M. 1995. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 85: 1881-1887.

Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Teresa A., Neri M., Neri A. 2001. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). British J. Haematol. 114: 362-364.

Ito T., Deng X., Carr B., May W.S. 1997. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272: 11671-11673.

Iwata T., Li C.L., Deng C.X., Francomano C.A. 2001. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Hum. Mol. Genet. 10: 1255-1264.

Jaakkola S., Salmikangas P., Nylund S., Partanen J., Armstrong E., Pyrhonen S., Lehtovirta P., Nevanlinna H. 1993. Amplification of fgfr4 gene in human breast and gynecological cancers. Int. J. Cancer. 54: 378-382.

Jang J.H., Shin K.H., Park J.G. 2001. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61: 3541-3543.

Jaye M., Schlessinger J., Dionne CA. 1992. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta. 1135: 185-199.

Jefferies H.B.J., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., Thomas G. 1997. Rapamycin suppresses 5’TOP mRNA translation through inhibition of p70^S6K. EMBO J. 16: 3693-3704.

Jeffers M., Schmidt L., Nakaigawa N., Webb CP., Weirich G., Kishida T., Zbar B., Vande Woude GF. 1997. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 94:11445-11450.

Jeng Y.M., Lin C.Y., Hsu H.C. 2000. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 154: 107-111.

Jhiang S.M. 2000. The RET proto-oncogene in human cancers. Oncogene. 19: 5590-5597.

Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C. 1999. The tyrosine kinase negative regulate c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 8: 309-312.

Johnson DE., Lu J., Chen H., Werner S., and Williams LT. 1991. The human fibroblast growth factor genes: a common structural arrangement underlies the mechanism for generating receptor forms that differ in their third immunoglobulin domain. Mol. Cell. Biol. 12: 82-88.

Johnson DE., and Williams LT. 1993. Structural and functionnal diversity in the FGF receptor multigene family. Adv. Cancer Res. 60: 1-41.

Jotterand Bellomo M., Muhlematter D., Wicht M., Delacretaz F., Schmidt P.M. 1992. t(8;9)(p11;q32) in atypical chronic myeloid leukaemia: a new cytogenetic-clinicopathologic association ? Br. J. Haematol. 81: 307-308.

Kahan C., Seuwen K., Meloche S., Pouysségur J. 1992. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. J. Biol. Chem. 267: 13369-13375.

Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty W., Dmitrovsky E., Evans R.M. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell. 66: 663-674.

Kamps M.P., Murre C., Sun XH., Baltimore D. 1990. A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell. 60: 547- 555.

Kamps MP., Wright DD., Lu Q. 1996. DNA-binding by oncoprotein E2A-Pbx1 is important for blocking differenciation but dispensable for fibroblast transformation. Oncogene. 12: 19-30.

Kanda S., Hodgkin M.N., Woodfield R.J., Wakelam M.J.O., Thomas G., Claesson-Welsh L. 1997. Phosphatidylinositol 3’-kinase-independent p70 S6 kinase activation by fibroblast growth factor receptor-1is important for proliferation but not differentiation of endothelial cells. J. Biol. Chem. 272: 23347-23353.

Kannan K., Givol D. 2000. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life. 49: 197-205.

Kantarjian H.M., Talpaz M., Dhingra K., Estey E., Keating M.J., Ku S., Trujillo J., Huh Y., Stass S., Kurzrock R. 1991. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 78: 2411-2418.

Kasper L.H., Brindle PK., Schnabel C.A., Pritchard C.E., Cleary ML., Van Deursen JM. 1999. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol. Cell. Biol. 19: 764-776.

Kaufmann S.H., Gores G.J. 2000. Apoptosis in cancer: cause and cure. BioEssays. 22: 1007-1017.

Kelekar A., Chang B.S., Harlan J.E., Fesik S.W., Thompson C.B. 1997. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-X_L. Mol. Cell. Biol. 17: 7040-7046.

Kennedy S.G., Kandel E.S., Cross T.K., Hay N. 1999. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell. Biol. 19: 5800-5810.

Kim I., Moon S.O., Yu KH., Kim UH., Young Koh G. 2001. A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas. Bioch. Biophy. Acta. 1518: 152-156.

Kitabayashi I., Aikawa Y., Yokoyama A., Hosoda F., Nagai M., Kakazu N., Abe T., Ohki M. 2001. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia. 15: 89-94.

Klagsbrun M., Baird A. 1991. A dual receptor system is required for basic fibroblast growth factor activity. Cell. 67: 229-231.

Klint P., Kanda S., Claesson-Welsh L. 1995. Shc and a novel 89-kDa component couple to the Grb2-Sos complex in fibroblast growth factor-2- stimulated cells. J. Biol. Chem. 270: 23337-23344.

Klint P., and Claesson-Welsh L. 1999. Signal transduction by fibroblast growth factor receptor. Frontiers in Bioscience. 4: 165-177.

Knezevich S.R., McFadden D.E., Tao W., Lim J.F., and Sorensen P.H.B. 1998. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 18: 184-187.

Knudson A.G. 2001. Two genetic hits (more or less) to cancer. Nature. 1: 157-162.

Koenigsmann M., Griffin J.D., DiCarlo J., and Cannistra S.A. 1992. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood. 79: 657-665.

Kohler M., Bauknecht T., Grimm M., Birmelin G., Kommoss F., Wagner E. 1992. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur. J. Cancer. 28A: 1432-1437.

Kouhara H., Hadari YR., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., Schlessinger J. 1997. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 89: 693-702.

Kroon E., Thorsteinsdottir U., Mayotte N., Nakamura T., Sauvageau G. 2001. NUP98-HOXA9 expression in hemopoieic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 20: 350-361.

Kuefer M.U., Look T., Pulford K., Behm F.G., Pattengale P.K., Mason D.Y., Morris S.W. 1997. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignacy in mice. Blood. 90: 2901-2910.

Kulkarni S., Reiter A., Smedley D., Goldman J.M., Cross N.C.P. 1999. The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. Genomics. 55: 118-121.

Kuno Y., Abe A., Emi N., Lida M., Yokozawa T., Towatari M., Tanimoto M., and Saito H. 2001. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood. 97:1050-1055.

Kurzrock R., Shtalrid M., Talpaz M., Kloetzer W.S., Gutterman J.U. 1987. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood. 70: 1584-1588.

Kuwabara T., Warashina M., Tanabe T., Tani K., Asano S., Taira K. 1998. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol. Cell. 2: 617-627.

Lacronique V., Boureux A., Valle V. D., Poirel H., Quang C.T., Mauchauffé M., Berthou C., Lessard M., Berger R., Ghysdael J., and Bernard O. A. 1997. A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia. Science. 278: 1309-1312.

Lacronique V., Boureux A., Monni R., Dumon S., Mauchauffé M., Mayeux P., Gouilleux F., Berger R., Gisselbrecht S., Ghysdael J., and Bernard O. A. 2000. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 95: 2076-2083.

Larsson H., Klint P., Landgren E., Claesson-Welsh L. 1999. Fibroblast growth factor receptor-1 mediated endothelial cell proliferation is dependent on the src homology (SH)2/SH3 domain-containing adaptor protein Crk. J. Biol. Chem. 274: 25726-25734.

Lengauer C., Kinzler K.W., Vogelstein B. 1998. Genetic instabilities in human cancers. Nature. 396: 643-649.

Leslie J., Barker T., Glancy M., Jennings B., Pearson J. 1994. t(8;13)(p11;q12) translocation in a myeloproliferative disorder associated with a T-cell non-Hodgkin lymphoma. British J. Haematol. 86: 876-878.

Leuenberger H.G.W., Kunstyr I. 1976. Gerontological data of C57BL/6J mice. II. Changes in blood cell counts in the course of natural aging. J. Gerontol. 31: 648-653.

Lewis J.P., Jenks H., Lazerson J. 1983. Philadelphia chromosome-negative chronic myelogenous leukaemia in a child with t(8;9)(p11or 12q34). Am. J. Pediatric Hematology/Oncology. 5: 265-269.

Lewis J.P., Welborn J.L., Meyers F.J., Levy N.B., Roschak T. 1987.Mast cell disease followed by leukemia with clonal evolution.Leukemia Res. 11: 769-773.

Lewis I.D., McDiarmid L.A., Samels L.M., To L.B., Hughes T.P. 1998. Establishment of a reproductible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 91: 630-640.

Li S., Ilaria R.L., Million R.P., Daley G.Q., Van Etten R.A. 1999a. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189: 1399-1412.

Li C., Chen L., Iwata T., Kitagawa M., Fu X.Y., Deng C.X. 1999b. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8: 35-44.

Liang J., Prouty L., Williams B.J., Dayton M.A., Blanchard K.L. 1998. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood. 92: 2118-2122.

Lijima Y., Ito T., Oikawa T., Eguchi M., Eguchi-Ishimae M., Kamada N., Kishi K., Asano S., Sakaki Y., and Sato Y. 2000. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood. 95: 2126-2131.

Liu Q., Schwaller J., Kutok J., Cain D., Aster JC., Williams IR., and Gilliland DG. 2000. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 19: 1827-1838.

Lockshin R.A., Zakeri Z. 2001. Programmed cell death and apoptosis: origins of the theory. Nature Mol. Cell. Biol. 2: 545-556.

Longley BJ., Metcalfe DD., Tharp M., Wang X., Tyrrell L., Lu SZ., Heitjan D., Ma Y. 1999. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. 96: 1609-1614.

Look T. 1997. Oncogenic transcription factors in the human acute leukemias. Science. 278: 1059-1064.

Lowenstein EJ., Daly RJ., Batzer AG., Li W., Margolis B., Lammers R., Ullrich A., Skolnik E.Y., Bar-Sagi D., Schlessinger J. 1992. The SH2 and SH3 domain- containing protein GRB2 links receptor tyrosine kinases to ras signalling. Cell. 70: 431-442.

Lu Y., Lin Y.Z., LaPushin R., Cuevas B., Fang X., Yu S.X., Davies M.A., Khan H., Furui T., Mao M., Zinner R., Hung M.C., Steck P., Siminovitch K., Mills G.B. 1999. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18: 7034-7045.

Lugo T.G., Pendergast A.N., Muller A.J., Witte O.N. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247: 1079-1082.

Lui V.W.Y, He Y., Goyal K., Huang L. 2001. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol. Ther. 3: 169-177.

Macdonald D., Aguiar RCT., Mason PJ., Goldman J.M., and Cross NCP. 1995. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11 : a review. Leukemia. 9: 1628-1630.

Mahgoub N., Taylor B.R., Gratiot M., Kohl N.E., Gibbs J.B., Jacks T., Shannon K.M. 1999. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 94: 2469-2476.

Majewski M., Nieborowska-Skorska M., Salomoni P., Slupianek A., Reiss K., Trotta R., Calabretta B., Skorski T. 1999. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 59: 2815-2819.

Makin G., Dive C. 2001. Apoptosis and cancer chemotherapy. Trends Cell Biol. 11: S22-S26.

Malbrain M.L.N.G., Van den Bergh H., Zachée P. 1996. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: a complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br. J. Haematol. 92:176-183.

Markowitz D., Goff S., Bank A. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62: 1120-1124.

Markowitz D., Hesdorffer C., Ward M., Goff S., Bank A. 1990. Retroviral gene transfer using safe and efficient packaging cell lines. Ann. NY. Acad. Sci. 612: 407-414.

Martiat P., Mecucci C., Nizet Y., Stul M., Philippe M., Cassiman J.J., Michaux J.L., Van den Berghe H., Sokal G. 1990. P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma. Leukemia. 4: 751-754.

Martin D.B., Nelson P.S. 2001. From genomics to proteomics: techniques and applications in cancer research. Trends in Cell Biol. 11: S60-S65.

Martinez-Climent J.A., Vizcarra E., Benet I., Marugan I., Terol M.J., Solano C., Arbona C., Tormo M., Comes A.M., Garcia-Conde. 1998. Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12). Leukemia. 12: 999-1000.

Maru Y. 2001. Molecular biology of chronic myeloid leukemia. Int. J. Hematol. 73: 308-322.

Mayer B.J., Hamaguchi M., Hanafusa H. 1988. A novel viral oncogene with structural similarity to phospholipase C. Nature. 332: 272-275.

McWhirter J.R., Galasso D.L., and Wang J.Y. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13: 7587-7595.

Meeker T.C., Hardy D., Willman C., Hogan T., and Abrams J. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. Blood. 76: 285-289.

Melo J.V., Myint H., Galton D.A., Goldman J.M. 1994. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia ? Leukemia. 8: 1795-1796.

Melo J.V. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88: 2375-2384.

Meyers S., Noel L., Hiebert SW. 1995. The t(8;21) fusion protein interferes with AML1B dependent transcriptional activation. Mol. Cell. Biol. 15: 1974-1982.

Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A., Abrams L.J., Graham J.M., Feingold M., Moeschler J.B., Rawnsley E., Scott A.F., Jabs E.W. 1996. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am. J. Hum. Genet. 58: 491-498.

Michaux L., Mecucci C., Velloso E.R.P., Dierlamm J., Criel A., Louwagie A., Van Orshoven A.V., Van den Berghe H. 1996. About the t(8;13)(p11;q12) clinico-pathologic entity. Blood. 87: 1658-1659.

Migliaccio E., Mele S., Salcini A.E., Pelicci G., Lai K., Superti F.G., Pawson T., Di F.P., Lanfrancone L., Pelicci P.G. 1997. Opposite effects of the p52^shc/p46^shc and p66^shc splicing isoforms on the EGF receptor-MAP kinase –fos signalling pathway. EMBO J. 16: 706-716.

Miki T., Fleming T.P., Bottaro D.P., Rubin J.S., Ron D., Aaronson S.A. 1991. Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science. 251: 72-75.

Million R.P., Van Etten R.A. 2000. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 96: 664-670.

Mitani K., Sato Y., Tojo A., Ishikawa F., Kobayashi Y., Miura Y., Miyazono K., Urabe A. Takaku F. 1990. Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa BCR-ABL protein. British J. Haematol. 76: 221-225.

Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa MK., Mano H., Yazaki Y., Ohki M., Hirai H. 1994. Generation of the AML1-EVi-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13: 504-510.

Mitelman F., Johansson B., Mertens F. 2001. Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman.

Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., Kamada N., Ohki M. 1993. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721.

Mohammadi M., Dionne A., Li W., Li N., Spivak T., Honegger A. M., Jaye M., and Schlessinger J. 1992. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature. 358: 681-684.

Mohammadi M., Dikic I., Sorokin A., Burgess WH., Jaye M., and Schlessinger J. 1996a. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 16: 977-989.

Mohammadi M., Schlessinger J. Hubbard R., 1996b. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell. 86: 577-587.

Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard R., and Schlessinger J. 1997. Structures of tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 246: 955-960.

Monica K., LeBrun DP., Dedera DA., Brown R., Cleary ML. 1994. Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable. Mol Cell Biol 14: 8304-8314.

Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A. 2000. The transmembrane mutation G380R in Fibroblast Growth factor Receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol. Cell. Biol. 20: 516-522.

Moritz T., Dutt P., Xiao X., Carstanjen D., Vik T., Hanenberg H., Williams D.A. 1996. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood. 88: 855-862.

Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., and Look T. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin’s lymphoma. Science. 263: 1281-1284.

Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., Wong A.J. 1995. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55: 5536-5539.

Muenke M., Schell U., Hehr A., Robin NH., Losken W., Schinzel A., Pulleyn LJ., Rutland P., Reardon W., Malcom S., Winter RM. 1994. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nature Genet. 8: 269-274.

Mugneret F., Chaffanet M., Maynadie M., Guasch G., Favre B., Casasnovas O., Birnbaum B., Pébusque M-J. 2000. The 8p12 Myeloproliferative disorder : t(8;19)(p12;q11.3), a novel translocation involving the FGFR1 gene. British J. Of Haematology. 110: 1-4.

Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., Tunnacliffe A., Ponder B.A.J. 1993. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363: 458-460.

Mulligan L.M., Eng C., Healey C.S., Clayton D., Kwok J.B.J., Gardner E., Ponder M.A., Frilling A., Jackson C.E., Lehnert H., Neumann H.P.H., Thibodeau S.N., Ponder B.A.J. 1994. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 6: 70-74.

Murakami H. , Iwashita T., Asai N., Shimono Y., Iwata Y., Kawai K., Takahashi M. 1999. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem. Biophys. Res. Commun. 262: 68-75.

Naeem R., Singer S., Fletcher J.A. 1995. Translocation t(8;13)(p11;q11-12) in stem cell leukemia/lymphoma of T-cell and myeloid lineages. Genes Chrom. Cancer. 12: 148-151.

Nakayama H., Inamitsu., Ohga S., Kai T., Suda M., Matsuzaki A., Ueda K. 1996. Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder ? British. J. Haematol. 92: 692-695.

Nagata H., Worobec A.S., Semere T., Metcalfe D.D. 1998. Elevated expression of the proto-oncogene c-kit in patients with mastocytosis. Leukemia. 12: 175-181.

Naski MC., Wang Q., Xu J., Ornitz DM. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature genet. 13: 233-237.

Neilson K.M., Friesel R. 1996. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J. Biol. Chem. 271: 25049-25057.

Neshat M.S., Raitano A.B., Wang H.G., Reed J.C., Sawyers C.L. 2000. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and –independent pathways: roles for phosphatidylinositol 3-kinase and raf. Mol. Cell. Biol. 20: 1179-1186.

Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. 28: 10314-10319.

Newton A.C. 1995. Protein kinase C: structure, function, and regulation. J. Biol. Chem. 270: 28495-28498.

Nguyen M.H.H., Ho J.M.Y., Beattie B.K., Barber D.L. 2001. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3’-kinase/protein kinase B signaling pathway. J. Biol. Chem. 276: 32704-32713.

Nieborowska-Skorska M., Wasik M.A., Slupianek A., Salomoni P., Kitamura T., Calabretta B., Skorski T. 1999. Signal transducer and activator of transcription (STAT)5 activation by BCR-ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189: 1229-1242.

Nieborowska-Skorska M., Slupianek A., Xue L., Zhang Q., Raghunath P.N., Hoser G., Wasik M.A., Morris S.W., Skorski T. 2001. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 61: 6517-6523.

Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L.F., Kitamura T. 1999. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 18: 4754-4765.

Nowell P., Hungerford D. 1960. Chromosomes of normal and leukemic human leucocytes. J. Natl. Cancer Inst. 25: 85.

Nucifora G., Rowley JD. 1995. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 86: 1-14.

Okazuka K., Toba K., Kawai K., Nikkuni K., Tsuchiyama J., Momoi A., Kanazawa N., Nagai K., Suzuki N., Aizawa Y. 2001. Extramedullary T lymphoid blast crisis representing an additional translocation, t(6;8)(q25;q22) in a patient with Philadelphia-positive chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leukemia Research. 25: 1089-1094.

Okuda K., Golub T.R., Gilliland D.G., Griffin J.D. 1996. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 13: 1147-1152.

Oldridge M., Wilkie A.O., Slaney S.F., Poole M.D., Pulleyn L.J., Rutland P., Hockley A.D., Wake M.J., Goldin J.H., Winter R.M., Reardon W., Malcolm S. 1995. Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum. Mol. Genet. 4: 1077-1082.

O’Neill T.J., Craparo A., Gustafson TA. 1994. Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two hybrid system. Mol. Cell. Biol. 14: 6433-6442.

Ong SH., Guy GR., Hadari YR., Laks S., Gotoh N., Schlessinger J. Lax I. 2000. FRS2 proteins recruit intracellular signalling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell. Biol. 20: 979-989.

Ong SH., Hadari YR., Gotoh N., Guy GR., Schlessinger J. Lax I. 2001. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl. Acad. Sci. 98: 6074-6079.

Ornitz D.M., Leder P. 1992. Ligand specificity and heparin dependence of fibroblast growth factor receptor 1 and 3. J. Biol. chem. 267: 16305-16311.

Ornitz D.M., Itoh N. 2001. Fibroblast growth factors. Genome Biol. 2: S3005.

Oscier D.G., Gardiner A., Dyer M. 1993. t(8;9) in chronic myeloid leukaemia. Br. J. Haematol. 83: 176-177.

Pandolfi P.P. 2001. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 20: 5726-5735.

Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R., Meloni G., Saglio G., Salvatore F., Rotoli B. 1996. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 88: 2410-2414.

Panek R.L., Lu G.H., Dahring T.K., Batley B.L., Connolly C., Hamby J.M., and Brown K.J. 1998. In Vitro Biological Characterization and Antiangiogenic effects od PD 166866, a selective Inhibitor of the FGF-1 Receptor Tyrosine Kinase. J. of Pharmac. and Exp. Therap. 286: 569-577.

Pang L., Sawada T., Decker S.J., Saltiel A.R. 1995. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270: 13585-13588.

Park W.J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J., Jones M.C., Jabs E.W. 1995. Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum. Mol. Genet. 4: 1229-1233.

Pawson T., Scott J.D. 1997. Signaling through scaffold, anchoring, and adaptor proteins.Science. 278: 2075-2080.

Pawson T., Nash P. 2000. Protein-protein interactions define specificity in signal transduction. Genes & Dev.. 14: 1027-1047.

Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., Baltimore D. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving p210 bcr/abl-transduced bone marrow. Blood. 92: 3780-3792.

Pearson R.B., Dennis P.B., Han J.W., Williamson N.A., Kozma S.C., Wettenhall R.E., Thomas G. 1995. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J. 14: 5279-5287.

Pébusque M.J., Chaffanet M., Popovici C., Birnbaum D. 2000. FGFR1 et MOZ, deux gènes clés dans les hémopathies malignes associées à des réarrangements de la région chromosomique 8p11-12. Bull. Cancer. 87: 887-894.

Pelicci G., Lanfrancone L., Grignani F., McGlade J., Cavallo F., Forni G., Nicoletti I., Grignani F., Pawson T., Pelicci P.G. 1992. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell. 70: 93-104.

Penault-Llorca F., Bertucci F., Adélaïde J., Parc P., Coulier F., Jacquemier J., Birnbaum D., deLapeyriere O. 1995. Expression of FGF and FGF receptor genes in human breast cancer. Int. J. Cancer. 61: 170-176.

Peters K.G., Marie J., Wilson E., Ives H. E., Escobedo J., Rosario M. D., Mirda D., and Williams L.T. 1992. Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca²⁺ flux but not mitogenesis. Nature. 358: 678-681.

Peters D.G., Hoover R.R., Gerlach M.J., Koh E.Y., Zhang H., Choe K., Kirschmeier P., Bishop R., Daley G.Q. 2001. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 97: 1404-1412.

Plotnikov A.N., Schlessinger J., Hubbard SR., Mohammadi M. 1999. Structural basis for FGF receptor dimerization and activation. Cell. 98: 641-650.

Plotnikov A.N., Hubbard SR., Schlessinger J., Mohammadi M. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell. 101: 413-424.

Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., Hawley R.G., Stewart A.K. 2000. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 95: 992-998.

Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., Parsons R. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten^+/- mice. Proc. Natl. Acad. Sci. 98: 10320-10325.

Ponder B.A.J. 2001. Cancer genetics. Nature. 411: 336-341.

Popovici C., Adélaïde J., Ollendorff V., Chaffanet M., Guasch G., Jacrot M., Leroux D., Birnbaum D., Pébusque M-J. 1998. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12;q12). Proc. Natl. Acad. Sci. USA. 95: 5712-5717.

Popovici C., Ollendorff V., Coulier F., Pébusque M-J., Birnbaum D. 1998. Les FGF et leurs récepteurs dans l’hématopoïèse normale et pathologique. Hématologie. 4: 361-369.

Popovici C., Zhang B., Grégoire M-J., Jonveaux P., Pochitaloff M., Birnbaum D., Pébusque M-J. 1999. The t(6;8)(q27;p11) Translocation in a Stem Cell Myeloproliferative Disorder Fuses a Novel Gene, FOP, to Fibroblast Growth Factor Receptor 1. Blood 93: 1381-1389.

Porter A.C., Vaillancourt R.R. 1998. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene. 16: 1343-1352.

Pulford K., Morris S.W., Mason D.Y. 2001. Anaplastic lymphoma kinase proteins and malignancy. Curr. Op. Hematol. 81: 231-236.

Raanani P., Segal E., Levi I.I., Bercowicz M., Berkenstat H., Avigdor A., Perel A., Ben-Bassat I.I. 2000. Diffuse Alveolar hemorrhage in acute promyelocytic leukemia patients treated with Atra- a manifestation of basic disease or the treatment. Leukemia Lymphoma. 37: 605-610.

Rabbitts T.H. 2001. Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene. 20: 5763-5777.

Rabin S.J., Cleghon V., Kaplan D.R. 1993. SNT, a differentiation-specific target of neurotrophic factor-induced tyrosine kinase activity in neurons and PC12 cells. Mol. Cell. Biol. 13: 2203-2213.

Raffioni S., Thomas D., Foehr E.D., Thompson L.M., Bradshaw R.A. 1999. Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. Proc. Natl. Acad. Sci. 96: 7178-7183.

Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R. 1999. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. 96: 2110-2115.

Rao P.H., Cesarman G., Coleman M., Verma R.S. 1992. Cytogenetic evidence for extramedullary blast crisis with t(8;13)(q11;p11) in chronic myelomonocytic leukemia. Acta Haematol. 88: 201-203.

Ravichandran K.S. 2001. Signaling via Shc family adapter proteins. Oncogene. 20: 6322-6330.

Redner R.L., Rush E.A., Faas S., Rudert W.A., Corey S.J. 1996. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin retinoic acid receptor fusion. Blood. 87: 882-886.

Reed J.C. 1995. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Cur. Op. Oncol. 7: 541-546.

Reed J.C. 2001. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 7: 314-319.

Reich A., Sapir A., Shilo B.Z. 1999. Sprouty is a general inhibitor of receptor tyrosine kinase signaling. Development. 126: 4139-4147.

Reifsnyder C., Lowell J., Clarke A., Pillus L. 1996. Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases. Nature Genet. 14: 42-49.

Reiter A., Sohal J., Kulkarni S., Chase A., MacDonald D.H., Aguiar R.C., Goncalves C., Hernandez J.M., Jennings B.A., Goldman J.M., Cross N.C. 1998. Consistent fusion of ZNF198 to the fibroblast growth factor receptor –1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 92: 1735-1742.

Reuther G.W., Lambert Q.T., Caligiuri M.A., Der C.J 2000. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol. Cell. Biol. 20: 8655-8666.

Richelda R., Ronchetti D., Baldini L., Cro L., Viggiano L., Marzella R., Rocchi M., Otsuki T., Lombardi L., Maiolo A.T., Neri A. 1997. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 90: 4062-4070.

Robertson SC., Tynan JA., Donoghue DJ. 2000. RTK mutations and human syndromes. Trends In Genet. 16: 265-271.

Rodrigues G.A., Park M. 1994. Oncogenic activation of tyrosine kinases. Curr. Op. in Genet. & Dev. 4: 15-24.

Rodrigues GA., Falasca M., Zhang Z., Ong SH., Schlessinger J. 2000. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol. Cell. Biol. 20: 1448-1459.

Romana S.P., Mauchauffe M., Le Coniat M., Chumakov I., Le Paslier D., Berger R., Bernard O.A. 1995. The t(12;21) of acute lymphoblastic leukemia results in a Tel-AML1 gene fusion. Blood. 85: 3662-3670.

Ronchetti D., Greco A., Compasso S., Colombo G., Dell’Era P., Otsuki T., Lombardi L., Neri A. 2001. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene. 20: 3553-3562.

Roumiantsev S., de Aos I.E., Varticovski L., Ilaria R.L., Van Etten R.A. 2001. The Src homology 2 domain of bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 97: 4-13.

Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet JM., Maroteaux P., Le Merrer M., Munnich A. 1994. Mutations in the gene encoding fibroblast growth factor receptor –3 in achondroplasia. Nature. 371: 252-254.

Rousseau F., el Ghouzzi V., Delezoide A.L., Legeai-Mallet L., Le Merrer M., Munnich A., Bonaventure J. 1996. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TDI). Hum. Mol. Genet. 5: 509-512.

Rowley J.D. 1999. The role of chromosome translocations in leukemogenesis. Sem. in Hematol. 36 (supl. 7): 59-72.

Rutland P., Pulleyn L.J., Reardon W., Baraitser M., Hayward R., Jones B., Malcolm S., Winter R.M., Oldridge M., Slaney S.F., Poole M.D., Wilkie A.O.M. 1995. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nature Genet. 9: 173-176.

Ruvolo P.P., Deng X., May W.S. 2001. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia. 15: 515-522.

Sahni M., Ambrosetti D.C., Mansukhani A., Gertner R., Levy D., Basilico C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13: 1361-1366.

Salomon-Nguyen F., Della-Valle V., Mauchauffé M., Busson-Le Coniat M., Ghysdael J., Berger R., and Bernard O. 2000. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc. Natl. Acad. Sc. USA. 97: 6757-6762.

Salomoni P., Condorelli F., Sweeney S.M., Calabretta B. 2000. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood. 96: 676-684.

Sanchez-Garcia I., Martin-Zanca. 1997. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol. 267: 225-228.

Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M.,Fusco A., Vecchio G., Matoskova B., Kraus M.H., Di Fiore P.P. 1995. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 267: 381-383.

Sattler M., Salgia R. 1997. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytok. Growth Factor Rev. 8: 63-79.

Sawyers C.L., Denny C.T., and Witte O.N. 1991. Leukemia and the disruption of normal hematopoiesis. Cell. 64: 337-350.

Scheid M.P., Duronio V. 1998. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/Akt: involvement of MEK upstream of Bad phosphorylation. Proc. Natl. Acad. Sci. 95: 7439-7444.

Schimmer A.D., Hedley D.W., Penn L.Z., Minden M.D. 2001. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood. 98: 3541-3553.

Schlessinger J. 2000a. Cell signaling by receptor tyrosine kinases. Cell. 103: 211-225.

Schlessinger J. 2000b. New roles of Src kinases in control of cell survival and angiogenesis. Cell. 100: 293-296.

Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M. 2000c. Crystal structure of a ternary FGF-FGFR-Heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell. 6: 743-750.

Schlessinger J., and Ullrich A. 1992. Growth factor signaling by receptor tyrosine kinases. Neuron. 9: 383-391.

Schmelzle T., Hall M.N. 2000. TOR, a central controller of cell growth. Cell. 103: 253-262.

Schmidt L., Duh FM., Chen F., Kishida T., Glenn G., Choyke P., Scherer SW., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim UR., Feltis JT., Casadevall C., Zamarron A., Bernues M., Richard S., Lips CJ., Walther MM., Tsui LC., Geil L., Orcutt ML., Stackhouse T., Zbar B., et al. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:68-73.

Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria R., Marynen P., Gilliland D.G. 1998. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17: 5321-5333.

Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., Lee C.K., Gerthner R., Kitamura T., Frantsve J., Anastasiadou E., Loh M.L., Levy D.E., Ihle J.N., Gilliland D.G. 2000. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell. 6: 693-704.

Ségal-Bendirdjian E. 1999. Mort cellulaire: signalisation et exécution de l’apoptose. Hématologie. 5: 376-387.

Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., Abraham R.T. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60: 3504-3513.

Sexl V., Piekorz R., Moriggl R., Rohrer J., Brown M.P., Bunting K.D., Rothammer K., Roussel M.F., Ihle J.N. 2000. Stat5a/b contribute to interleukin7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. Blood. 96: 2277-2283.

Shain KH., Landowski TH., and Dalton WS. 2000. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr. opin. in Oncol. 12: 557-563.

Shannon K. 1995. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr. Op. In Hematol. 2: 305-308.

Shaoul E., Reich-Slotky R., Berman B., Ron D. 1995. Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene. 10: 1553-1561.

Shiang R., Thompson L.M., Zhu Y.Z., Church D.M., Fielder T.J., Bocian M., Winokur S.T., Wasmuth J.J. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 78: 335-342.

Sibley K., Stern P., Knowles M.A. 2001. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors. Oncogene. 20: 4416-4418.

Sinclair H., Van der Berg Goldman J.M., and Cross N.C.P. 2000. Identification of four new variant translocations involving FGFR1 in myeloproliferative disorders with a propensity to evolve into AML. Abstract of the 42^nd Annual Meeting of the American Society of Hematology.

Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., Wasik M.A., Tsichlis P.N., Calabretta B. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16: 6151-6161.

Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235: 177-182.

Sleeman M., Fraser J., McDonald M., Yuan S., White D., Grandison P., Kumble K., Watson J.D., Murison J.G. 2001. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 271: 171-182.

Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione A., Majewski M., Xue L., Morris S.W., Wasik M.A., Skorski T. 2001. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61: 2194-2199.

Smedley D., Hamoudi R., Clark J., Warren W., Abdul-Rauf M., Somers G., Venter D., Fagan K., Cooper C., Shipley J. 1998. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 to a novel gene RAMP. Hum. Mol. Genet. 7: 637-642.

Smedley D., Demiroglu A., Abdul-Rauf M., Heath C., Cooper C., Shipley J., Cross N.C.P. 1999. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia. 1: 349-355.

Smith J.M., Mayer B.J. 2002. ABL: mechanisms of regulation and activation. Frontiers in Bioscience. 7: d31-42.

Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., Cordon-Cardo C., Lowe S.W. 2001. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 409: 207-211.

Sohal J., Chase A., Mould S., Corcoran M., Oscier D., Wilkins B., Iqbal S., Parker S., Welborn J., Harris R.I., Martinelli G., Montefusco V., Wymann, MP., Pirola L. 1998. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta. 1436:127-150.

Sohal J., Chase A ., Iqbal S., Parker S., Goldman J.M., and Cross N.C.P. 1999. Two color FISH to detect FGFR1 rearrangements in myeloproliferative disorders : identification of the t(8;17)(p11;q25) as a new cytogenetic variant. Blood. 94: 180b.

Sohal J., Chase A., Mould S., Corcoran M., Oscier D., Iqbal S., Parker S., Welborn J., Harris R.I., Martinelli G., Montefusco V., Sinclair P., Wilkins B.S., van den Berg H., Vanstraelen D., Goldman J.M., Cross N.C.P. 2001. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer. 32: 155-163.

Somers G.R., Slater H., Rockman S., Ekert H., Southey M.C., Chow C.W., Armes J.E., Venter D.J. 1997. Coexistent T-cell lymphoblastic lymphoma and an atypical myeloproliferative disorder associated with t(8;13)(p21;q14). Pediatric Pathol. Lab. Med. 17: 141-158.

Songyang Z., Shoelson S.E., Chaudhuri M., Gish G., Pawson T., Haser W.G., King F., Roberts T., Ratnofsky S., Lechleider R.J., Neel BG., Birge R.B., Fajardo J.E., Chou M.M., Hanafusa H., Schaffhausen B., Cantley L.C. 1993. SH2 domains recognize specific phosphopeptide sequences. Cell. 72: 767-778.

Songyang Z., Baltimore D., Cantley L.C., Kaplan D.R., Franke TF. 1997. Interleukin 3-dependent survival by the Akt protein kinase. Proc. Natl. Acad. Sci. 94: 11345-11350.

Sorokin A., Mohammadi M., Huang J., Schlessinger J. 1994. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. J. Biol. Chem. 269: 17056-17061.

Sözeri O., Kerstin V., Liyanage M., Frith D., Kour G., Mark III G.E., Stabel S. 1992. Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene. 7: 2259-2262.

Spain L.M., Mulligan R.C. 1992. Purification and characterization of retrovirally transduced hematopoietic stem cells. Proc. Natl. Acad. Sci. 89: 3790-3794.

Spangrude G.J., Smith L., Uchida N., Ikuta K., Heimfeld S., Friedman J., Weissman I.L. 1991. Mouse hematopoietic stem cells. Blood. 78: 1395-1402.

Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchasi D., Huang J., Jaye M., Crumley G., Schlessinger J., and Lax I. 1994. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation and cell proliferation. Cell. 79: 1015-1024.

Spivak-Kroizman T., Mohammadi M., Hu P., Jaye M., Schlessinger J., and Lax I. 1994b. Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation. J. Biol. Chem. 269: 14419-14423.

Spritz RA., Giebel LB., Holmes SA. 1992. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am. J. Hum. Genet. 50: 261-269.

Stam J.C., Geerts W.J.C., Versteeg H.H., Verkleij A.J., van Bergen en Henegouven P.M.P. 2001. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt. J. Biol. Chem. 276: 25176-25183.

Stauber D.J., DiGabriele AD., Hendrickson WA. 2000. Structural interactions of fibroblast growth factor receptor with its ligand. Proc. Natl. Acad. Sci. 97: 49-54.

Stehelin D., Varmus H.E., Bishop J.M., Vogt P.K. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 260: 170-173.

Stein R.C., and Waterfield M.D. 2000. PI3-kinase inhibition: a target for drug development ? Mol. Med. Today 6: 347-357.

Still I.H., Chernova O., Hurd D., Stone R.M., Cowell J.K. 1997. Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 90: 3136-3141.

Strissel PS., Strick R., Rowley JD., Zeleznik-Le NJ. 1998. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site co-localize near exon 9 in the MLL breakpoint cluster region. Blood. 92: 3793-3803.

Su W.C.S., Kitagawa M., Xue N., Xie B., Garofalo S., Cho J., Deng C., Horton W.A., Fu X.Y. 1997. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature. 386: 288-292.

Szeberenyi J., Cai H., and Cooper G.M. 1990. Effect of a dominant inhibitory Ha-ras mutation on neuronal differentiation of PC12 cells. Mol. Cell. Biol. 10: 5324-5332.

Taki T., Sako M., Tsuchida M., Hayashi Y. 1997. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 89: 3945-3950.

Tanabe T., Kuwabara T., Warashina M., Tani K., Taira K., Asano S. 2000. Oncogene inactivation in a mouse model. Nature. 406: 473-474.

Tanaka T., Mitani K., Kurokawa M., Ogawa S., Tanaka K., Nishida J., Yazaki Y., Shibata Y., Hirai H. 1995. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol. Cell. Biol. 15: 2383-2392.

Tannheimer S.L., Rehemtulla A., Ethier S.P. 2000. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res. 2: 311-320.

Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.Z., Wilkin DJ., Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J. 1995a. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature genet. 9: 321-328.

Tavormina P.L., Rimon D.L., Cohn D.H., Zhu Y.Z., Shiang R., Wasmuth J.J. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 1995b. Hum. Mol. Genet. 4: 2175-2177.

Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E., McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J., Donoghue D.J., Thompson L.M., Francomano C.A. 1999. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. Am. J. Hum. Genet. 64: 722-731.

Theillet C., Adélaïde J., Louason G., Bonnet-Dorion F., Jacquemier J., Adnane J., Longy M., Katsaros D., Sismondi P., Gaudray P., Birnbaum D. 1993. FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chrom. Cancer. 7: 219-226.

Thomas G., Hall M.N. 1997. TOR signalling and control of cell growth. Cur. Op. Cell Biol. 9: 782-787.

Thorsteinsdottir U., Krosl J., Kroon E., Haman A., Hoang T., Sauvageau G. 1999. The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells. Mol. Cell. Biol. 19: 6355-6366.

Tlsty T.D., White A., and Sanchez J. 1992. Suppression of gene Amplification in human cell Hybrids. Science. 255: 1425-1427.

Tomasson M.H., Williams I.R., Li S., Kutok J., Cain D., Gillessen S., Dranoff G., Van Etten R.A., Gilliland D.G. 2001. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. Blood. 97: 1435-1441.

Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. 1984. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 226: 1097-1099.

Twigg S.R., Burns H.D., Oldridge M., Heath J.K., Wilkie A.O. 1998. Conserved use of a non-canonical 5’ splice site (/GA) in alternative splicing by fibroblast growth factor receptors 1, 2 and 3. Hum. Mol. Genet. 7: 685-691.

Uckun FM., Herman-Hatten K., Crotty ML., Sensel MG., Sather HN., Ahlgren LT., Sarquis MB., Bostrom B., Nachman JB., Steinherz PG., Gaynon PS., Heerema N. 1998. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;14)(q21;q23) chromosomal translocation. Blood. 92: 810-821.

Ugolini F., Adélaïde J., Charafe-Jauffret E., Nguyen C., Jacquemier J., Jordan B., Birnbaum D., Pébusque M.J. 1999. Differential expression assay of chromosome arm 8p genes identifies Frizzlzed-related (FRP1/FRZB) and Fibroblast growth factor receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene. 18: 1903-1910.

Ullrich A., and Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell. 61: 203-212.

van de Rijn M., Heimfeld S., Spangrude G.J., Weissman I.L. 1989. Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc. Natl. Acad. Sci. 86: 4634-4638.

van den Berg H., Kroes W., van der Schoot C.E., Dee R., Pals S.T., Bouts T.H.M., Slater R.M. 1996. A young child with acquired t(8;9)(p11;q34): additional proof that 8p11 is involved in mixed myeloid/T lymphoid malignancies. Leukemia. 10: 1252-1253.

Vandergoten P., Janssen M., Madoe V., Vanstraelen D. 1998. A myeloproliferative disorder with eosinophilia, a translocation t(8;9)(p22;23) and a cerebellar degeneration in regression with interferon alpha therapy. Acta Hematol. 100 (Suppl.): 8

van der Maarel SM., Scholten IH., Hubert I., Philippe C., Suijkerbuijk RF., Gilgenkrantz S., Kere J., Cremers FPM., Ropers H.H. 1996. Cloning and characterization of DXS66773E, a candidate gene for X-linked mental retardation in Xq13.1. Hum. Mol. Genet. 5: 887-897.

Van Etten R.A. 2001a. Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models. Cur. Op. Hematol. 8: 224-230.

Van Etten R.A. 2001b. Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol. Dis. 27: 201-205.

van Hemert M.J., de Steensma H.Y., van Heusden G.P.H. 2001. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. BioEssays. 23: 936-946.

Vannier J.P., Bizet M., Bastard C., Bernard A., Ducastelle T., Tron P. 1984. Simultaneous occurrence of a T-cell lymphoma and a chronic myelogenous leukemia with an unusual karyotype. Leukemia Res. 8: 647-657.

Vickers M. 1996. Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br. J. Haematol. 94: 1-4.

Vogt P.K. 2001. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol. Med. 7: 482-484.

Von Gise A., Lorenz P., Wellbrock C., Hemmings B., Berberich-Siebelt F., Rapp U.R., Troppmair J. 2001. Apoptosis suppression by Raf-1 and MEK1 requires MEK and phosphatidylinositol 3-kinase-dependent signals. Mol. Cell. Biol. 21: 2324-2336.

Voss J., Posern G., Hannemenn J.R., Wiedemann L.M., Turhan A.G., Poirel H., Bernard O., Adermann K., Kardinal C., Feller S.M. 2000. The leukaemic oncoproteins Bcr-Abl and tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene. 19: 1684-1690.

Wai D.H., Knezevich S.R., Lucas T., Jansen B., Kay R.J., Sorensen P.H.B. 2000. The ETV6-NTRK3 gene fusion encodes a chimeric protein kinase that transforms NIH3T3 cells. Oncogene. 19: 906-915.

Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., Williams R.L. 2000. Structural determinants of phosphoinositide-3-kinase by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6: 909-919.

Wallenius V., Hisaoka M., Helou K., Levan G., Mandahl N., Meis-Kindblom J.M., Kindblom L.G., Jansson J.O. 2000. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracelular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am. J. Pathol. 156: 821-829.

Wang J-K., Gao G., and Goldfarb M. 1994. Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol. Cell. Biol.. 14: 181-188.

Wang J-K., Xu H., Li HC., Goldfarb M. 1996. Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of ras. Oncogene. 13: 721-729.

Wang J-K., and Goldfarb M. 1997. Amino acid residues which distinguish the mitogenic potentials of two FGF receptors. Oncogene. 14: 1767-1778.

Wang H.G., Rapp U.R., Reed J.C. 1996. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 87: 629-638.

Webster MK., and Donoghue DJ. 1996a. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15: 520-527.

Webster MK., D'Avis PY., Robertson SC., Donoghue DJ. 1996b. Profound ligand- independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for the lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16: 4081-4087.

Webster MK., and Donoghue DJ. 1997a. FGFR activation in skeletal disorders: too much of a good thing. Trends. In. Genet.. 13: 178-182.

Webster MK., and Donoghue DJ. 1997b. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol. Cell. Biol. 17: 5739-5747.

Weide R., Rieder H., Mehraein Y., Wolf M., Kaiser U., Seifart U., Görg C., Havemann K. 1997. Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br. J. Haematol. 96:117-123.

Weiner DB., Liu J., Cohen JA., Williams WV., Greene M. 1989. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature. 339: 230-231.

Weissman I.L. 2000. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science. 287: 1442-1446.

Wellmann A., Doseeva V., Butscher W., Raffeld M., Fukushima P., Stetler-Stevenson M., Gardner K. 1997. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 11: 965-972.

Wells R.A., Catzavelos C., Kamel-Reid S. 1997. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat. Genet. 17: 109-113.

Weng Q.P., Andrabi K., Klippel A., Kozlowski M.T., Williams L.T., Avruch J. 1995. Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc. Natl. Acad. Sci. 92: 5744-5748.

Werner S., Weinberg W., Liao X., Peters K.G., Blessing M., Yuspa S.H., Weiner R.L., Williams L.T. 1993. Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. EMBO J. 12: 2635-2643.

Westervelt P., Ley T. 1999. Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood. 93: 2143-2148.

Wiedemann M., Trueb B. 2000. Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. Genomics. 69: 275-279.

Wilkie AOM., Slaney SF., Oldridge M ., Poole MD., Ashworth GJ., Hockley AD., Hayward RD., David DJ., Pulleyn LJ., Rutland P., Malcolm S., Winter RM., Reardon W. 1995a. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nature Genet. 9: 165-172.

Wilkie A.O.M., Morriss-Kay G.M., Jones E.Y., Heath J.K. 1995b. Functions of fibroblast growth factors and their receptors. Curr. Biol. 5: 500-507.

Wilks A.F. 1993. Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer. Adv. Cancer Res. 60: 43-73.

Willis TG., Dyer MJS. 2000. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 96: 808-822.

Wilson G., Frost L., Goodeve A., Vandenberghe E., Peake I., Reilly J. 1997. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia. Blood. 89: 3064.

Wong E.S.M., Lim J., Low B.C., Chen Q., Guy G.R. 2001a. Evidence for direct interaction between Sprouty and Cbl. J. Biol. Chem. 276: 5866-5875.

Wong S., Witte O.N. 2001b. Modeling philadelphia chromosome positive leukemias. Oncogene. 20: 5644-5659.

Wu R., Connolly D., Ngelangel C., Bosch X., Munoz N., Cho K.R. 2000. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene. 19: 5543-5546.

Wymann MP., Pirola L. 1998. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta. 1436: 127-150.

Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., Stone R., Weissman S.M., Hudson T.J., and Fletcher J.A. 1998. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia / lymphoma syndrome. Nat.Genet. 18: 84-87.

Xu H., Lee KW., Goldfarb M. 1998. Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins. J. Biol. Chem. 273: 17987-17990.

Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., Taniwaki M., Matsuda A., Bessho M. 2001. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res. 61: 8371-8374.

Yamaguchi T.P., Harpal K., Henkemeyer M., Rossant J. 1994. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev. 8: 3032-3044.

Yang E., Zha J., Jockel E.J., Boise L.H., Thompson C.B., Korsmeyer S.J. 1995. Bad, a heterodimeric partner for Bcl-X_L and Bcl-2, displaces Bax and promotes cell death. Cell. 80: 285-291.

Yarden Y., Sliwkowski M.X. 2001. Untangling the ErbB signalling network. Nature. 2: 127-137.

Yayon A., Klagsbrun M., Esko JE., Leder P., Ornitz DM. 1991. Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64: 841-848.

Yenush L., White MF. 1997. The IRS-signalling system during insulin and cytokine action. BioEssays. 19: 491-500.

Yu K., Herr A.B., Waksman G., Ornitz D.M. 2000. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc. Natl. Adad. Sci. 97: 14536-14541.

Yuan Z.Q., Sun M., Felman R.I., Wang G., Ma X.L., Jiang C., Coppola D., Nicosia S.V., Cheng J.Q. 2000. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 19: 2324-2330.

Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X_L. Cell. 87: 619-628.

Zhang B.X., Ren R. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony- stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 92: 3829-3840.

Zhang X., Wong R., Hao S.X., Pear W.S., Ren R. 2001a. The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood. 97: 277-287.

Zhang X., Subrahmanyam R., Wong R., Gross A.W., Ren R. 2001b. The NH₂-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol. Cell. Biol. 21: 840-853.

Zhao R.C., Jiang Y., Verfaillie C.M. 2001. A model of human p210^bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector. Blood. 97: 2406-2412.

Zhou H., Li X.M., Meinkoth J., Pittman R.N. 2000. Akt regulates cell survival and apoptosis at a postmitochondrial level. J. Cell Biol. 151: 483-494.

Zörnig M., Hueber A.O., Baum W., Evan G. 2001. Apoptosis regulators and their role in tumorigenesis. Bioch. Biophys. Acta. 1551: F1-F37.

Zou H., Li Y., Liu X., Wang X. 1999. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274: 11549-11556.

Cette bibliographie est issue de la THESE de Doctorat de Géraldine Guasch, 06 mars 2002, Université d'Aix-Marseille II
"Caractérisation moléculaire du syndrome myéloprolifératif 8p12 impliquant le gène FGFR1"
Directeur de Thèse : Mme le Docteur Marie-Josèphe Pébusque
© Copyright Université Aix-Marseille II 2002